Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries and affiliates or offices in five countries.
Company profile
Ticker
NVO, NONOF
Exchange
Website
CEO
Lars Fruergaard Joergensen
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
NVO stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
3 Jun 24
6-K
Current report (foreign)
28 May 24
6-K
Current report (foreign)
17 May 24
SD
Conflict minerals disclosure
17 May 24
6-K
Current report (foreign)
15 May 24
6-K
Current report (foreign)
13 May 24
6-K
Current report (foreign)
13 May 24
6-K
Current report (foreign)
6 May 24
6-K
Current report (foreign)
6 May 24
6-K
Current report (foreign)
6 May 24
Latest ownership filings
SC 13G/A
BlackRock Inc.
6 Feb 24
11-K
Annual report of employee stock purchases
27 Jun 23
11-K
Annual report of employee stock purchases
27 Jun 23
SC 13G/A
BlackRock Inc.
23 Feb 23
11-K
Annual report of employee stock purchases
28 Jun 22
11-K
Annual report of employee stock purchases
28 Jun 22
SC 13G/A
BlackRock Inc.
1 Feb 22
11-K
Annual report of employee stock purchases
23 Jun 21
11-K
Annual report of employee stock purchases
23 Jun 21
SC 13G/A
BlackRock Inc.
29 Jan 21
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2024
9.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1654 |
Opened positions | 493 |
Closed positions | 106 |
Increased positions | 592 |
Reduced positions | 395 |
13F shares | Current |
---|---|
Total value | 35.80 tn |
Total shares | 321.27 mm |
Total puts | 4.93 mm |
Total calls | 5.29 mm |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Jennison Associates | 21.08 mm | $2.71 tn |
FMR | 17.60 mm | $2.26 tn |
Fisher Asset Management | 13.72 mm | $1.76 tn |
BAC Bank Of America | 13.05 mm | $1.68 tn |
MS Morgan Stanley | 12.01 mm | $1.54 tn |
Fayez Sarofim & Co | 11.82 mm | $1.52 tn |
Renaissance Technologies | 10.79 mm | $1.38 bn |
Loomis Sayles & Co L P | 8.85 mm | $1.14 bn |
Folketrygdfondet | 8.76 mm | $1.12 tn |
T. Rowe Price | 8.59 mm | $1.10 bn |
News
$100 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
3 Jun 24
Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes
31 May 24
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
30 May 24
Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs
30 May 24
Jim Cramer Recommends Buying Apple, Finds This Tech Stock 'Very Interesting'
29 May 24
Press releases
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors
4 Jun 24
Novo Nordisk launches national Wegovy® campaign, Power of Wegovy®
3 Jun 24
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
29 May 24
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
21 May 24
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
17 May 24